SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ABV-1703

ABVC·ABVC BIOPHARMA, INC.
BEARISH
Drug Impact Rating2/10
Trial phase
Preclinical / undisclosed
Time to market
Not estimable. No clinical trials have been registered or reported for ABV-1703, and no development timeline has been disclosed.
Why 2/10
No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ABV-1703 in the next ~12 months. The drug was mentioned only once in a 2022 pipeline update as a pancreatic cancer candidate, and no clinical trial record, IND filing, or development milestone has been publicly reported since. With zero upcoming binary events, the impact score is low.
Actionable Insight BEARISH

ABV-1703 appears to be a dormant or very early-stage pipeline asset. The company's financial filings and press releases since 2022 have not mentioned any clinical progress for this drug. Investors should watch for any mention of ABV-1703 in future SEC filings or press releases as a sign of renewed development, but the drug is not a near-term value driver.

Price Chart

Loading chart...

Executive Summary

ABV-1703 is an oncology drug candidate from ABVC BioPharma (NASDAQ: ABVC) that was mentioned once in an August 2022 pipeline update as being developed for pancreatic cancer. Since then, no clinical trials, IND filings, or development milestones have been publicly reported. ABVC is a micro-cap biotech (~$0.91/share) with zero product revenue, a going concern warning, and recent dilutive convertible note financings. ABV-1703 appears to be a stalled or very early-stage program with no near-term catalyst and negligible visibility.

How It Works

Not publicly disclosed. ABV-1703 is described only as an oncology/hematology product candidate for pancreatic cancer, but its mechanism of action has not been detailed in any available public source.

Trial Status

ABV-1703 was identified in an August 2022 ABVC BioPharma press release as an oncology candidate for the treatment of pancreatic cancer. No IND application, clinical trial registration, patient enrollment, or data readout has been publicly reported since that date. The drug is not listed in any ClinicalTrials.gov record associated with ABVC.

The Two-Sided Case

▲ Bull Case2
ABV-1703 targets pancreatic cancer, a large unmet medical need with significant market opportunity.
ABVC has executed licensing deals for other oncology assets (ABV-1519, ABV-1501), suggesting the company may find a partner for ABV-1703 as well.
▼ Bear Case5
ABV-1703 has had zero publicly reported clinical progress since a single mention in August 2022, suggesting the program is dormant or deprioritized.
ABVC is a micro-cap company with severe financial distress: zero product revenue, a going concern warning, and recent dilutive convertible note financings (e.g., $3.39M private placement closed November 2026).
No clinical trial records, IND filings, or regulatory milestones exist for ABV-1703 in any public database.
The pancreatic cancer treatment landscape has become more competitive with the 2026 FDA approval of Revolution Medicines' Rasonque (daraxonrasib), a breakthrough oral RAS inhibitor.
ABVC's quant composite score is -32 (negative), with a 12-month return of -69.6%, reflecting severe stock underperformance.

Upcoming Catalysts

  • None identified. No clinical readouts, regulatory decisions, or development milestones are scheduled for ABV-1703.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report

Sources · 4

Hover a chip for the title
1 markets.financialcontent.com2 markets.financialcontent.com3 cbsnews.com4 sec.gov